Abrysvo or Arexvy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to unmet need for rsv vaccines, aging population growth, respiratory infection burden, regulatory approvals, public health awareness.

The growth in the forecast period can be attributed to expanding elderly demographics, rising rsv hospitalization rates, broader vaccination recommendations, improved access through providers, preventive healthcare focus. Major trends in the forecast period include growing focus on rsv prevention, rising vaccination in older adults, expansion of adult immunization programs, hospital and community vaccine delivery, preventive care for high risk populations.

The increasing prevalence of respiratory syncytial virus (RSV) infections is expected to drive the growth of the Abrysvo or Arexvy market in the coming years. RSV infections, caused by the respiratory syncytial virus, primarily affect the respiratory tract, usually resulting in mild cold-like symptoms but potentially causing severe illness in infants, older adults, and immunocompromised individuals. The rising prevalence of RSV infections is attributed to the virus’s high contagiousness, seasonal outbreaks, limited population immunity, and heightened vulnerability among high-risk groups such as infants and the elderly. Abrysvo addresses RSV prevalence by providing targeted vaccines that protect these vulnerable populations from severe RSV-related illness. For example, in October 2024, the U.S. Centers for Disease Control and Prevention reported that during the 2024-25 season, RSV-related hospitalizations reached 3.2 per 100,000 individuals. Consequently, the growing prevalence of RSV infections is driving the Abrysvo or Arexvy market.

Rising healthcare expenditure is also expected to propel the Abrysvo or Arexvy market. Healthcare spending, driven by aging populations, advancements in medical technology, the growing prevalence of chronic diseases, higher demand for services, and increasing costs of pharmaceuticals, supports investment in advanced treatment options, including vaccines and biologic therapies. For example, in May 2023, the UK’s Office for National Statistics reported that healthcare spending increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022, reaching approximately $317.63 billion (£292 billion). Therefore, increasing healthcare expenditure is contributing to growth in the Abrysvo or Arexvy market.

Leading companies in the Abrysvo or Arexvy market are focusing on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, to enhance protection, improve safety, and address high-risk populations. Bivalent RSVpreF vaccines are designed to provide immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, a key site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a U.S.-based pharmaceutical company, received FDA approval for ABRYSVO, a bivalent RSVpreF vaccine for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk. The vaccine’s indication also covers pregnant individuals between 32 and 36 weeks of gestation, offering protection to infants from birth to six months.

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the abrysvo or arexvy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the abrysvo or arexvy market by increasing costs associated with vaccine manufacturing inputs and distribution packaging. These impacts are most apparent in hospital and public vaccination programs across north america and europe. Higher import duties have affected large scale procurement pricing. Supply chain coordination has also faced regulatory delays. However, tariffs are supporting regional vaccine manufacturing investments and improving long term supply stability.

The abrysvo or arexvy market research report is one of a series of new reports that provides abrysvo or arexvy market statistics, including abrysvo or arexvy industry global market size, regional shares, competitors with a abrysvo or arexvy market share, detailed abrysvo or arexvy market segments, market trends and opportunities, and any further data you may need to thrive in the abrysvo or arexvy industry. This abrysvo or arexvy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Abrysvo (also known as Arexvy) is a vaccine developed to prevent respiratory syncytial virus (RSV) infection in adults aged 60 and older. It is intended to reduce the risk of severe RSV-related illness, which can cause serious respiratory complications in older adults.

The main clinical indications for Abrysvo or Arexvy are RSV prevention and infant protection. RSV prevention involves using medical interventions or vaccines to lower the risk of infection by the respiratory syncytial virus, which can result in significant respiratory issues, particularly in infants, older adults, and immunocompromised individuals. It is applicable to various age groups, including adults (18-59 years), older adults (60+ years), and pregnant individuals (32-36 weeks of gestation). End users include healthcare providers, pregnant individuals, and high-risk adults.

The abrysvo or arexvy market consists of sales of prefilled syringes, vaccine vials, vaccine storage equipment, syringes, and needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.